Apollomics (NASDAQ:APLM) Trading Up 8.4% – Still a Buy?

Apollomics Inc. (NASDAQ:APLM)’s stock price rose 8.4% during trading on Wednesday . The stock traded as high as $29.98 and last traded at $29.18. Approximately 28,279 shares were traded during mid-day trading, a decline of 46% from the average daily volume of 51,948 shares. The stock had previously closed at $26.93.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Apollomics in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

Apollomics Trading Up 8.4%

The firm has a 50-day simple moving average of $13.71 and a 200 day simple moving average of $8.72.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.